皓元医药:拟使用不超5亿元闲置募集资金进行现金管理

Core Viewpoint - The company plans to issue convertible bonds to raise a net amount of 812 million yuan in 2024, aiming to enhance the efficiency of fund utilization [1] Group 1: Fundraising and Management - The company intends to raise 812 million yuan through the issuance of convertible bonds to unspecified investors [1] - To improve fund utilization efficiency, the company plans to use up to 500 million yuan of idle raised funds for cash management, investing in principal-protected financial products [1] - The cash management period will be effective for 12 months starting from December 12, 2025, with funds being available for rolling use [1] Group 2: Governance and Compliance - The board of directors has approved the cash management plan, which does not require submission for shareholder meeting approval [1] - The company previously encountered an issue where an employee mistakenly exceeded the authorized limit by 49 million yuan for cash management, but this excess has now been redeemed [1] - The sponsoring institution has no objections to the proposed cash management plan [1]